Abstract
Ocular surface may be affected by various rare congenital diseases. Anterior segment dysgenesia and congenital panocular diseases affecting ocular surface is usually from genetic origin. The ocular surface in aniridia may present progressive opacities due to limbal insufficiency creating Aniridia Associative Keratopathy (AAK). Molecular genetics usually reveals PAX6 gene mutation or deletion. Gene therapies in eyedrop form and repurposing drugs are tested for their efficacy and safety in congenital aniridia. Mechanisms and physiopathology of new gene therapies and drugs will be developed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
